Harvard panel explores challenges of Alzheimer’s drug trials

first_img By Sharon Begley April 15, 2016 Reprints Dina Rudick/The Boston Globe Senior Writer, Science and Discovery (1956-2021) Sharon covered science and discovery. [email protected] About the Author Reprints The challenges of clinical trials, particularly those testing Alzheimer’s disease drugs, was the focus of an hour-long panel discussion on Friday. The event was hosted by the Forum at Harvard T.H. Chan School of Public Health, in collaboration with STAT.The program was presented in partnership with HHMI Tangled Bank Studios and in association with NOVA, whose film “Can Alzheimer’s Be Stopped?” examines the hurdles to developing and testing experimental treatments for the disease.Missed the event live? The video is available in its entirety below.advertisementcenter_img Sharon Begley In the LabHarvard panel explores challenges of Alzheimer’s drug trials @sxbegle Tags Alzheimer’sclinical trialsHarvard T.H. Chan School of Public Healthlast_img

Leave a Reply

Your email address will not be published. Required fields are marked *

*
*